An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

ANNOUNCE 2: An open-label phase 1b, and a randomized, double-blind phase 2 study of olaratumab with gemcitabine plus docetaxel in the treatment of patients with advanced soft tissue sarcoma (STS)

Annals of Oncology ◽

10.1093/annonc/mdw388.26 ◽

2016 ◽

Vol 27 ◽

pp. vi491

Author(s):

A. Redondo ◽

C. Valverde Morales ◽

N. Hindi ◽

J.A. Lopez-Martin ◽

G. Honigschmidt ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Open Label ◽

Advanced Soft Tissue Sarcoma ◽

Double Blind ◽

Phase 2 Study ◽

Open Label Phase ◽

Phase 1B

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”

European Journal of Cancer ◽

10.1016/j.ejca.2021.04.015 ◽

2021 ◽

Vol 152 ◽

pp. 26-40

Author(s):

Patrick Schöffski ◽

Maud Toulmonde ◽

Anna Estival ◽

Gloria Marquina ◽

Monika Dudzisz-Śledź ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Kinase Inhibitor ◽

Single Agent ◽

Phase 2 ◽

Efficacy And Safety ◽

First Line ◽

Phase 2 Study ◽

Line Chemotherapy

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyw175 ◽

2016 ◽

Vol 47 (2) ◽

pp. 137-144 ◽

Cited By ~ 23

Author(s):

Akira Kawai ◽

Nobuhito Araki ◽

Yoichi Naito ◽

Toshifumi Ozaki ◽

Hideshi Sugiura ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Phase 2 Study ◽

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial

Cancer Science ◽

10.1111/cas.14148 ◽

2019 ◽

Vol 110 (9) ◽

pp. 2894-2904 ◽

Cited By ~ 4

Author(s):

Kenji Tamura ◽

Kosei Hasegawa ◽

Noriyuki Katsumata ◽

Koji Matsumoto ◽

Hirofumi Mukai ◽

...

Keyword(s):

Cervical Cancer ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Japanese Patients ◽

Uterine Cervical Cancer ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Trial ◽

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00056-5 ◽

2021 ◽

Author(s):

Robert L Coleman ◽

Domenica Lorusso ◽

Christine Gennigens ◽

Antonio González-Martín ◽

Leslie Randall ◽

...

Keyword(s):

Cervical Cancer ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30109-1 ◽

2020 ◽

Vol 21 (5) ◽

pp. 671-684 ◽

Cited By ~ 68

Author(s):

Ghassan K Abou-Alfa ◽

Vaibhav Sahai ◽

Antoine Hollebecque ◽

Gina Vaccaro ◽

Davide Melisi ◽

...

Keyword(s):

Locally Advanced ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Faculty Opinions recommendation of Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717988709.793474324 ◽

2013 ◽

Author(s):

Richard Gorlick ◽

Jonathan Gill

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30325-9 ◽

2020 ◽

Vol 21 (8) ◽

pp. 1110-1122

Author(s):

Aaron R Weiss ◽

Yen-Lin Chen ◽

Thomas J Scharschmidt ◽

Yueh-Yun Chi ◽

Jing Tian ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Preoperative Chemoradiotherapy ◽

Pathological Response ◽

High Grade ◽

Phase 2 ◽

Open Label ◽

Intermediate Grade ◽

Phase 2 Trial ◽

Faculty Opinions recommendation of Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.731932303.793579335 ◽

2020 ◽

Author(s):

Nathalie Gaspar

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Bone Sarcoma ◽

Phase 2 ◽

Open Label ◽

Advanced Soft Tissue Sarcoma ◽

Phase 2 Trial ◽